EXAGEN INC.
XGNNasdaq
$4.39
↑ +3.3%Jul 17 close · end-of-day
Price
1Y↓ -37.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$104.7M
Enterprise Value
$106.1M
P/E
—
P/S
1.5
P/B
7.3
EV/EBITDA
—
PEG
—
FCF Yield
-13.5%
Dividend Yield
—
Revenue (TTM)
$68.4M
Net Income (TTM)
-$20.2M
Free Cash Flow (TTM)
-$14.1M
Gross Margin
58.3%
Operating Margin
-20.6%
Net Margin
-29.5%
ROE
-139.7%
ROIC
-70.6%
Debt / Equity
1.6
Net Cash
-$1.4M
Return 1Y
-38.9%
Company profile
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases. Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases.
- CEO
- John Aballi
- Sector
- Services
- Industry
- Healthcare
- Employees
- 220
- Headquarters
- California
- Website
- exagen.com
Management & directors
- Aballi JohnPresident and CEO
- Black Jeffrey G.Chief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
XGN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$17.3M↑ +11.7%
Diluted EPS-$0.17↓ -15.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $42.0M | $48.3M | $45.6M | $52.5M | $55.6M | $66.6M |
| Gross profit | — | — | — | $29.5M | $33.1M | $38.8M |
| Operating income | -$15.2M | -$24.1M | -$46.1M | -$22.8M | -$13.6M | -$14.1M |
| Net income | -$16.7M | -$26.9M | -$47.4M | -$23.7M | -$15.1M | -$20.0M |
| Diluted EPS | -$1.32 | -$1.68 | -$2.77 | -$1.34 | -$0.83 | -$0.93 |
| Operating cash flow | -$14.1M | -$20.3M | -$32.1M | -$14.5M | -$13.3M | -$13.6M |
| Free cash flow | -$14.5M | -$22.6M | -$36.5M | -$15.3M | -$13.8M | -$14.3M |
| Gross margin | — | — | — | 56.1% | 59.5% | 58.3% |
| Operating margin | -36.2% | -49.8% | -101.1% | -43.5% | -24.5% | -21.1% |
| Net margin | -39.8% | -55.6% | -104.0% | -45.1% | -27.2% | -30.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.1M | $12.5M | $13.7M | $15.5M | $17.2M | $17.2M | $16.6M | $17.3M |
| Gross profit | $9.1M | $7.0M | $8.5M | $9.1M | $10.4M | $10.1M | $9.2M | $10.2M |
| Operating income | -$2.6M | -$4.7M | -$3.4M | -$3.4M | -$2.6M | -$3.1M | -$5.0M | -$3.4M |
| Net income | -$3.0M | -$5.0M | -$3.8M | -$3.8M | -$4.4M | -$7.1M | -$4.7M | -$4.0M |
| Diluted EPS | -$0.16 | -$0.28 | -$0.20 | -$0.20 | -$0.21 | -$0.31 | -$0.21 | -$0.17 |
| Operating cash flow | -$2.4M | -$2.2M | $363,000.00 | -$10.7M | -$2.9M | $2.9M | -$3.0M | -$10.4M |
| Free cash flow | -$2.6M | -$2.3M | $217,000.00 | -$10.8M | -$3.1M | $2.7M | -$3.1M | -$10.6M |
| Gross margin | 60.1% | 55.8% | 62.1% | 58.9% | 60.4% | 58.4% | 55.4% | 59.0% |
| Operating margin | -17.2% | -37.3% | -24.8% | -21.7% | -15.3% | -18.0% | -29.9% | -19.7% |
| Net margin | -19.7% | -40.2% | -27.5% | -24.2% | -25.8% | -41.1% | -28.1% | -22.9% |
Company news
Jun 19, 2026
May 28, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-12 | Black Jeffrey G.· Chief Financial Officer | Award | 75,000 | $3.16 | $237,000.00 | filing |
| 2026-03-12 | ABALLI JOHN· President and CEO | Award | 150,000 | $0.00 | $0.00 | filing |
| 2026-03-03 | ABALLI JOHN· President and CEO | Sale | 15,698 | $3.62 | $56,826.76 | filing |
| 2026-03-03 | ABALLI JOHN· President and CEO | Award | 2,535 | $3.08 | $7,800.20 | filing |
| 2026-02-27 | Black Jeffrey G.· Chief Financial Officer | Award | 1,511 | $3.08 | $4,649.35 | filing |
| 2026-02-24 | ABALLI JOHN· President and CEO | Sale | 11,430 | $3.61 | $41,262.30 | filing |
| 2026-02-24 | Black Jeffrey G.· Chief Financial Officer | Sale | 1,584 | $3.61 | $5,718.24 | filing |
| 2025-10-16 | ABALLI JOHN· President and CEO | Sale | 31,787 | $11.82 | $375,598.37 | filing |
| 2025-09-02 | Black Jeffrey G.· Chief Financial Officer | Sale | 20,466 | $9.79 | $200,362.14 | filing |
Latest 9 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.